Filing Analysis
Precision BioSciences announced the dosing of the first patient in its Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD at Arkansas Children’s Hospital. This represents a clinical milestone in the company's Duchenne muscular dystrophy treatment program.
📋 Key Facts
- First patient dosed in Phase 1/2 FUNCTION-DMD clinical trial.
- Trial evaluates PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).
- Clinical site: Arkansas Children’s Hospital.
- The announcement was made via press release on August 24, 2026.
Precision BioSciences, Inc. filed an 8-K to announce its financial results and business update for the quarter ended June 30, 2026. The filing serves as a formal announcement of quarterly earnings via a press release.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Quarter ended June 30, 2026
- The company issued a press release (Exhibit 99.1) containing financial results and a business update.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Precision BioSciences, Inc. announced a significant restructuring of its executive leadership team effective August 1, 2026. This includes the promotion of the current CFO to COO and the appointment of a new CFO and Chief Accounting Officer.
🚩 Red Flags
- Significant turnover/reshuffling in key financial leadership roles (CFO and CAO changes) within a single filing.
- Internal promotion of the outgoing CFO to COO can sometimes indicate internal restructuring or shifting priorities, though the company explicitly denies disagreement.
📋 Key Facts
- Alex Kelly promoted from CFO to Chief Operating Officer (COO), effective August 1, 2026.
- Naresh Tanna appointed as new Chief Financial Officer (CFO), effective August 1, 2026.
- Mei Burris designated as Principal Accounting Officer and Chief Accounting Officer, effective August 1, 2026.
- Alex Kelly's new compensation: $510,000 base salary + 45% target annual bonus.
- Naresh Tanna's new compensation: $400,000 base salary + 40% target annual bonus (pro-rated for 2026).
- The company explicitly stated the CFO transition was not due to any disagreement regarding operations or accounting practices.
Precision BioSciences updated its corporate presentation to highlight clinical data from its PBGENE-HBV study and provide updates on the expansion of its Duchenne muscular dystrophy (DMD) clinical trial site.
📋 Key Facts
- PBGENE-HBV ELIMINATE-B study showed a 1-log (10-fold) reduction in cccDNA-derived transcripts via liver biopsy data.
- Next program update for PBGENE-HBV is targeted for year-end 2026.
- Activated a second clinical site for the FUNCTION-DMD trial at Washington University School of Medicine.
- Initial safety data for PBGENE-DMD is expected by year-end 2026.
Precision BioSciences, Inc. entered into a First Amendment to its Amended and Restated Loan and Security Agreement with Banc of California on June 10, 2026. The primary purpose of the amendment was to extend the maturity date of the company's Term Loan.
📋 Key Facts
- Agreement date: June 10, 2026
- Lender: Banc of California
- The maturity date of the Term Loan was extended from June 30, 2027, to December 31, 2029
- The amendment modifies a previous agreement dated July 31, 2024
Precision BioSciences announced new biopsy and clinical data from the Phase 1 ELIMINATE-B trial for chronic hepatitis B (PBGENE-HBV). The data shows a 10-fold reduction in cccDNA-derived transcripts and 100% pgRNA loss in patients with detectable pgRNA at baseline.
🚩 Red Flags
- One patient experienced two serious adverse events (SAEs) in the highest dose cohort, although the company claims these are now mitigated.
📋 Key Facts
- PBGENE-HBV demonstrated a 1-log (10-fold) reduction in cccDNA-derived transcripts.
- pgRNA loss was achieved in 100% of patients (n=6) with detectable pgRNA at baseline.
- 38 doses administered across 16 patients in 5 cohorts for safety analysis.
- No dose limiting toxicities observed.
- One patient in the highest dose cohort (0.8 mg/kg) experienced two serious adverse events (SAEs) related to hypotension.
- Mitigation protocols (slower infusion rate, increased steroids) have been implemented to address hypotension and LNP-related ALT/AST abnormalities.
Precision BioSciences, Inc. reported the results of its annual meeting of stockholders held on May 21, 2026. Stockholders approved an amendment to the 2019 Incentive Award Plan to increase the share pool by 3,800,000 shares and approved an amendment to the Certificate of Incorporation to allow for officer exculpation.
🚩 Red Flags
- Significant stockholder opposition to Proposal 4 (Incentive Award Plan amendment) with 8,145,992 votes against versus 11,170,635 votes for, indicating potential investor concern over dilution.
📋 Key Facts
- Stockholders approved an amendment to the 2019 Incentive Award Plan, increasing the shares of Common Stock available for issuance by 3,800,000 shares.
- An amendment to the Certificate of Incorporation was approved and filed on May 22, 2026, to provide for the exculpation of certain officers as permitted by Delaware law.
- Melinda Brown and Geno Germano were elected as Class I directors to serve until 2029.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Precision BioSciences announced its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 5, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing was signed by John Alexander Kelly, Chief Financial Officer.
Precision BioSciences hosted a Key Opinion Leader (KOL) event on March 17, 2026, to discuss the Duchenne muscular dystrophy (DMD) treatment landscape and the company's clinical progress. The event focused on the PBGENE-DMD program and the FUNCTION-DMD Phase 1/2 clinical trial.
📋 Key Facts
- The event featured Dr. Aravindhan Veerapandiyan, a pediatric neurologist, and Pat Furlong, Founding President of Parent Project Muscular Dystrophy.
- The presentation provided an overview of the PBGENE-DMD program and the FUNCTION-DMD Phase 1/2 clinical trial.
- The company furnished the presentation materials as Exhibit 99.1.
- The event was held via live webcast on March 17, 2026, at 9:00 a.m. ET.
Precision BioSciences, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
📋 Key Facts
- Filing date: March 12, 2026
- Reporting period: Quarter and fiscal year ended December 31, 2025
- The company furnished the information under Item 2.02 (Results of Operations and Financial Condition)
- John Alexander Kelly, Chief Financial Officer, signed the report
Precision BioSciences announced that the FDA has cleared an Investigational New Drug (IND) application for its PBGENE-DMD program. This clearance allows the company to begin clinical trial site activities for the FUNCTION-DMD Phase 1/2 study.
📋 Key Facts
- FDA granted IND clearance for the PBGENE-DMD program targeting Duchenne muscular dystrophy (DMD).
- The clearance enables initiation of clinical trial site activities for the FUNCTION-DMD Phase 1/2 clinical study.
- The company aims to activate its first U.S. clinical site in the first half of 2026.
Precision BioSciences provided a preliminary update on its 2025 year-end cash position and outlined key clinical trial milestones for 2026. The company reports a strong liquidity position with an expected cash runway extending through 2028.
🚩 Red Flags
- Financial results for FY2025 are unaudited and subject to change following the ongoing audit.
📋 Key Facts
- Preliminary cash, cash equivalents, and restricted cash as of Dec 31, 2025: ~$137 million (unaudited).
- Expected cash runway extends through 2028 via existing cash, potential licensee payments, and ATM facility.
- ELIMINATE-B trial (PBGENE-HBV) biopsy data expected in H1 2026.
- FUNCTION-DMD Phase 1/2 clinical trial expects first patient dosing in late Q1 or early Q2 2026.
- Initial FUNCTION-DMD data anticipated by year-end 2026.
Precision BioSciences, Inc. entered into an underwriting agreement with Guggenheim Securities, LLC to conduct a public offering of common stock and warrants. The offering aims to raise approximately $70.0 million in net proceeds to fund R&D and working capital.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 10 million new shares and accompanying warrants.
- Warrant exercise price ($7.25) is significantly higher than the offering price ($6.14), indicating a gap between current valuation and future upside for existing holders.
📋 Key Facts
- Offering size: 10,815,000 shares of Common Stock and accompanying one-half warrants to purchase up to 5,407,500 shares.
- Pre-funded warrants component: Up to 1,400,000 pre-funded warrants and accompanying one-half warrants to purchase 700,000 shares.
- Combined offering price: $6.14 per share/unit (pre-funded at $6.139995).
- Warrant terms: Five-year term with an exercise price of $7.25 per share; immediately exercisable.
- Estimated net proceeds: Approximately $70.0 million after fees and expenses.
- Closing date: Expected to occur on November 12, 2025.
- Use of proceeds: Research and development, working capital, and general corporate purposes.
Precision BioSciences issued a press release detailing clinical data from its ELIMINATE-B Phase 1 study for PBGENE-HBV, showing dose-dependent antiviral activity and first molecular evidence of HBV gene editing in humans. The company plans to complete Cohort 3 administrations by Q1 2026 and move toward an expansion phase.
🚩 Red Flags
- None identified in this clinical update filing.
📋 Key Facts
- ELIMINATE-B Phase 1 study evaluating PBGENE-HBV for Hepatitis B showed consistent HBsAg reduction across all treated patients regardless of baseline levels (370 to 11,813 IU/mL).
- Cohort 2 (0.4 mg/kg) achieved durable HBsAg declines maintained for at least 8 weeks after the first administration.
- A liver biopsy from a patient in Cohort 2 provided direct molecular evidence of ARCUS-mediated gene editing (indels) in viral DNA.
- Safety profile was reported as favorable with no dose-limiting toxicities; adverse events were transient and generally resolved within 12 hours.
- The company expects to finalize Cohort 3 administrations in the first quarter of 2026.
Precision BioSciences, Inc. filed an 8-K to announce the release of its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended September 30, 2025.
- Filing date: November 3, 2025.
- Financial results are provided via press release in Exhibit 99.1.
Precision BioSciences entered into amended and restated employment agreements for its Section 16 officers to facilitate retention. The amendments include updated compensation terms, lump-sum severance provisions triggered by change in control or restructuring, and the establishment of escrow accounts to fund these obligations.
🚩 Red Flags
- The inclusion of specific triggers for severance related to 'restructuring events' suggests the company may be preparing for or anticipating significant organizational changes.
- Requirement to fund cash severance in an escrow account indicates a potential liquidity commitment that could impact working capital.
📋 Key Facts
- Amended employment agreements signed on August 26, 2025, for CEO Michael Amoroso, CFO Alex Kelly, General Counsel Dario Scimeca, and CRO Jeff Smith.
- Agreements include updated annual base salaries and target bonus amounts.
- Severance provisions now trigger upon 'change in control' or a 'restructuring event'.
- Cash severance and potential expenses must be funded into an escrow account with JPMorgan Chase Bank, N.A.
Precision BioSciences, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings results (Item 2.02).
- Financial results pertain to the fiscal quarter ending June 30, 2025.
- The press release containing the actual financial data is attached as Exhibit 99.1.
Precision BioSciences announced positive Phase 1 safety and efficacy data from Cohort 1 of its ELIMINATE-B clinical trial evaluating PBGENE-HBV for hepatitis B. The data showed the treatment was well-tolerated with significant HBsAg reductions in patients, including one patient achieving a durable antiviral response.
🚩 Red Flags
- One patient in Cohort 2 experienced a transient infusion-related serious adverse event, though the DMC deemed it not dose-related or dose-limiting.
📋 Key Facts
- ELIMINATE-B Cohort 1 (0.2 mg/kg) reported no Grade 3+ adverse events or dose-limiting toxicities across three patients.
- HBsAg reductions in Cohort 1 were 56%, 69%, and 47% compared to baseline.
- One of three patients (33%) achieved a durable HBsAg reduction of ~50% maintained for seven months post-initial dose.
- Cohort 2 (0.4 mg/kg) data shows no adverse events above Grade 2 and no clinically significant liver transaminase elevations.
- The Data Monitoring Committee (DMC) recommended the initiation of Cohort 3 due to a favorable safety profile.
Precision BioSciences held its annual meeting of stockholders on May 28, 2025. The company successfully elected two Class III directors and ratified Deloitte & Touche LLP as independent auditors, but failed to pass a proposal to amend the Certificate of Incorporation regarding officer exculpation.
🚩 Red Flags
- Failure to pass Proposal 5 (Officer Exculpation) due to insufficient total votes cast relative to all outstanding shares.
📋 Key Facts
- Annual meeting held on May 28, 2025; quorum represented ~71% of outstanding common stock.
- Kevin J. Buehler and Shari Lisa Piré were elected as Class III directors.
- Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending Dec 31, 2025.
- Advisory votes on executive compensation frequency resulted in a preference for an annual vote.
- Proposal to amend Certificate of Incorporation regarding officer exculpation failed to meet the required threshold of >50% of all outstanding shares.
Precision BioSciences, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025 and updated its corporate investor presentation.
📋 Key Facts
- Announced financial results for the fiscal quarter ended March 31, 2025 via press release (Exhibit 99.1).
- Updated the company's corporate deck on the official investor relations website.
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
Precision BioSciences, Inc. issued an 8-K to provide a regulatory update regarding its PBGENE-DMD program via a press release and announced an upcoming webcast scheduled for May 15, 2025.
📋 Key Facts
- Company issued a press release on May 14, 2025, updating the status of its PBGENE-DMD program.
- A live webcast/conference call is scheduled for May 15, 2025, at 8:00 a.m. ET.
- The filing was signed by CFO John Alexander Kelly.
Precision BioSciences, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 26, 2025
- Reporting period: Quarter and fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Precision BioSciences, Inc. has completed a reclassification of its Board of Directors following the resignation of Sam Wadsworth, Ph.D. This process involved shifting two directors into different classes and reducing the total Board size from seven to six members.
🚩 Red Flags
- Reduction in Board size (from 7 to 6) can sometimes indicate shifting governance dynamics, though here it is presented as a structural reclassification.
📋 Key Facts
- Board reclassified three director classes into three classes of equal size on March 4, 2025.
- Michael Amoroso reclassified from Class I to Class II director.
- Melinda Brown reclassified from Class III to Class I director.
- The Board size was reduced from seven directors to six directors following a recommendation from the Nominating and Corporate Governance Committee.
- The changes were not due to any disagreements with the Company regarding operations, policies, or practices.
Precision BioSciences, Inc. announced the resignation of Sam Wadsworth, Ph.D. from its Board of Directors effective January 23, 2025.
📋 Key Facts
- Sam Wadsworth, Ph.D. resigned from the Company's Board of Directors on January 23, 2025.
- The resignation is due to his intention to retire from service on company boards.
- The filing explicitly states the resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Precision BioSciences reported preliminary year-end 2024 cash positions and confirmed the receipt of a $2.5 million deferred payment from TG Subsidiary, involving both cash and the issuance of 220,712 shares of common stock.
🚩 Red Flags
- Reliance on 'at-the-market' (ATM) facility for future liquidity indicates potential future dilution.
- Cash runway is projected into the second half of 2026, which remains a critical milestone period for clinical data readouts.
📋 Key Facts
- Estimated cash, cash equivalents, and restricted cash as of Dec 31, 2024: ~$108.5 million (pre-January inflows).
- Received $2.5 million in deferred cash from TG Subsidiary on January 6, 2025.
- Issued 220,712 shares of common stock to TG Subsidiary as part of the License Agreement terms.
- Management expects cash runway to extend into the second half of 2026 via existing cash, CAR T transactions, and ATM facility availability.
Precision BioSciences, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024.
🚩 Red Flags
- No specific red flags identified in the text of this 8-K; it is a routine earnings announcement filing.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 4, 2024.
Precision BioSciences announced regulatory progress for its lead gene-editing candidate and provided a preliminary cash position update. The company received Clinical Trial Application (CTA) clearance in Moldova for PBGENE-HBV.
🚩 Red Flags
- Preliminary/unaudited financial figures provided; actual results may vary significantly upon audit completion.
📋 Key Facts
- Preliminary cash, cash equivalents, and restricted cash expected to be approximately $121 million as of September 30, 2024.
- Received Clinical Trial Application (CTA) clearance in Moldova for lead candidate PBGENE-HBV (treatment for chronic hepatitis B).
- The company is an emerging growth company.
- Financial results for the quarter ended Sept 30, 2024, are currently undergoing review by independent auditors.
Precision BioSciences announced the retirement of Chief Medical Officer Alan List, effective September 13, 2024. Dr. List will transition into a strategic advisory role as a clinical consultant to ensure continuity in clinical strategy.
🚩 Red Flags
- Departure of a key C-suite officer (CMO) can sometimes signal internal friction or strategic shifts, though the transition to an advisory role mitigates this risk.
📋 Key Facts
- Dr. Alan List is retiring as Chief Medical Officer effective September 13, 2024.
- Dr. List will transition to a strategic advisory role/clinical consultant.
- The consulting agreement includes an hourly fee of $325 per hour.
- Outstanding unvested restricted stock units (RSUs) held by Dr. List will continue to vest during the term of the consulting agreement.
- The company will pay Dr. List's COBRA premiums through December 31, 2024.
- Dr. Murray Abramson, M.D., M.P.H. has been appointed as Senior Vice President, Head of Clinical Development.
- John Fry has been appointed as Strategic Clinical Advisor specializing in hepatitis.
Precision BioSciences announced the maturity of a $13 million convertible note related to its strategic transaction with Imugene Limited. The settlement includes $9.75 million in cash and $3.25 million in Imugene ordinary shares.
🚩 Red Flags
- Maturity of a significant convertible note ($13M) can impact liquidity depending on the company's current cash position.
- Settlement involves receiving equity in another company (Imugene), which may indicate a preference for non-cash settlement to preserve existing cash reserves.
📋 Key Facts
- Maturity of a $13 million convertible note reached on September 3, 2024.
- The note was part of a strategic transaction with Imugene Limited regarding azercabtagene zapreleucel (azer-cel).
- Settlement components: $9.75 million in cash and $3.25 million in Imugene ordinary shares.
Precision BioSciences, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2024.
📋 Key Facts
- The filing is a routine announcement of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended June 30, 2024.
- Filing date: August 1, 2024.
- The full press release containing the actual financial data is attached as Exhibit 99.1.
Precision BioSciences held its annual meeting of stockholders on June 4, 2024. The company successfully elected two Class II directors and approved the amendment/restatement of its 2019 Incentive Award Plan.
📋 Key Facts
- Annual meeting held on June 4, 2024.
- Stanley R. Frankel, M.D. and Samuel Wadsworth, Ph.D. elected as Class II directors (terms until 2027).
- Ratification of Deloitte & Touche LLP as independent auditor for the year ending Dec 31, 2024.
- Approved amendment to the 2019 Incentive Award Plan, increasing available shares by 630,000 plus annual increases through 2029.
- Quorum represented approximately 75% of common stock outstanding as of April 8, 2024 record date.
Precision BioSciences, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended March 31, 2024.
- Filing date: May 13, 2024.
Precision BioSciences entered into a non-brokered private placement of 25,000 common shares to its top management team at a 13.5% premium to the market price. The transaction is intended to raise approximately $300,000 for research and development initiatives.
🚩 Red Flags
- Related-party transaction: The entire offering is being sold to company insiders (CEO, CFO, General Counsel, and Chief Research Officer).
- Small scale capital raise: $300,000 is a very low amount for a public company, suggesting potential liquidity constraints.
- Premium pricing: Insiders are paying 13.5% above the market price, which can sometimes be used to mask underlying stock weakness or signal management's lack of confidence in immediate price appreciation.
📋 Key Facts
- Total shares issued: 25,000 common stock
- Offering price per share: $12.00 (a 13.5% premium to the preceding closing price)
- Aggregate gross proceeds: Approximately $300,000
- Purpose of funds: To fund ongoing research and development initiatives
- Closing date: Expected May 8, 2024
Precision BioSciences announced the termination of its development and license agreement with Prevail Therapeutics (a subsidiary of Eli Lilly) effective July 10, 2024. The company is exercising a reversion option to regain control over the programs but faces significant loss of potential milestone payments and royalties.
🚩 Red Flags
- Loss of major strategic partner (Eli Lilly/Prevail Therapeutics) significantly reduces non-dilutive funding potential.
- Significant loss of projected milestone revenue ($390M+ per product).
- The company must now fund the development of these programs independently or find new partners.
📋 Key Facts
- Prevail Therapeutics terminated the Amended and Restated Development and License Agreement without cause.
- Termination effective date: July 10, 2024.
- The agreement involved three genetic disorder targets (DMD, PBGENE-LLY2, and PBGENE-LLY3).
- Potential lost milestones were estimated at $390M to $395M per licensed product plus royalties in the mid-single to low-teens percentage range.
- Precision BioSciences is exercising a 'Reversion Option' to regain rights, data, and materials related to the programs.
- Company reports approximately $137 million in cash and cash equivalents as of March 31, 2024.
Precision BioSciences, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- The filing was made on March 27, 2024.
- Reports financial results for the period ending December 31, 2023.
- Includes a press release as Exhibit 99.1.
Precision BioSciences, Inc. entered into an underwriting agreement with Guggenheim Securities, LLC to conduct a public offering of 2.5 million shares of common stock and accompanying warrants at $16.00 per share/warrant combo. The company expects net proceeds of approximately $37.1 million to fund R&D and working capital.
🚩 Red Flags
- Warrant overhang: Issuance of 2.5 million warrants could lead to future dilution if exercised at $20.00.
- Funding dependency: The use of proceeds for 'working capital' often indicates a need for immediate liquidity to sustain operations.
📋 Key Facts
- Offering size: 2,500,000 shares of common stock and 2,500,000 warrants.
- Underwriter: Guggenheim Securities, LLC.
- Price per share/warrant combo: $16.00.
- Warrants terms: Five-year term; exercise price of $20.00 per share; immediately exercisable.
- Estimated net proceeds: Approximately $37.1 million.
- Expected closing date: March 5, 2024.
- Underwriter option to purchase up to 375,000 additional shares and warrants.
Precision BioSciences, Inc. has implemented a 1-for-30 reverse stock split effective February 13, 2024. The action was previously authorized by stockholders and is intended to adjust the company's share price.
🚩 Red Flags
- Reverse stock split (often used to combat delisting due to low share price).
- Management's forward-looking statements explicitly mention the risk of meeting minimum per share bid price requirements for Nasdaq listing.
📋 Key Facts
- Implemented a 1-for-30 reverse stock split on February 13, 2024.
- The split ratio was approved by shareholders at a special meeting on January 18, 2024.
- Every 30 shares of common stock were reclassified into one new share.
- Fractional shares will be paid out in cash based on the closing price on February 13, 2024.
- Trading on Nasdaq is expected to resume on a split-adjusted basis on February 14, 2024, under symbol 'DTIL'.
- New CUSIP number: 74019P 207.
Precision BioSciences entered into new employment agreements with its key executive officers, including the CEO, CFO, General Counsel, and Chief Research Officer. The updates primarily adjust base salaries, target bonuses, and significantly increase severance packages and benefit terms.
🚩 Red Flags
- Increased severance liabilities and benefit obligations for key management personnel.
📋 Key Facts
- New employment agreements executed on January 22, 2024, for Michael Amoroso (CEO), Alex Kelly (CFO), Dario Scimeca (General Counsel), and Jeff Smith (CRO).
- Agreements reflect updated current annual base salaries and target bonus amounts.
- Severance for CEO Michael Amoroso includes 18 months of salary/COBRA and accelerated vesting for up to 25 months, compared to 12-13 months for other officers.
- Change in control provisions provide enhanced severance (up to 24 months salary) if termination occurs near a transaction.
Precision BioSciences, Inc. held a special meeting of stockholders on January 18, 2024, where shareholders approved a proposal to amend the certificate of incorporation to effect a reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split is often used to combat delisting notices or improve share price, which can be a sign of financial distress.
- The wide range of the split (1-for-10 to 1-for-30) indicates significant uncertainty regarding the required ratio.
📋 Key Facts
- Special Meeting held on January 18, 2024.
- Proposal 1: Approval of a reverse stock split with a ratio between 1-for-10 and 1-for-30, as determined by the Board.
- Proposal 1 received 71,771,593 votes FOR out of total votes cast.
- Quorum reached: 83,328,647 shares (approx. 68.34% of Common Stock outstanding).
- Proposal 2 (adjournment to solicit more proxies) was also approved but deemed unnecessary as Proposal 1 passed.
Precision BioSciences entered into a significant license agreement with TG Therapeutics to develop non-oncological applications of its CAR T therapy, azer-cel. The deal includes up to $308.6 million in potential cash and milestone payments, though some components involve equity issuances at a 200% premium to VWAP.
🚩 Red Flags
- Equity issuance component: Part of the upfront payment involves issuing shares at a significant premium (200% VWAP) which may indicate a desire to avoid immediate cash depletion or complex valuation structuring.
- Control/Governance issues: TG Therapeutics has been granted an irrevocable proxy over issued shares for three years, potentially diluting shareholder voting power and control.
📋 Key Facts
- Entered into License Agreement with TG Subsidiary (TG Therapeutics) on January 7, 2024.
- Total potential consideration includes $10.0M upfront, $7.5M initial milestone, and up to $288.6M in additional milestones.
- Upfront payment structure: $5.25M cash, $2.25M via issuance of 2,920,816 shares (at 200% VWAP), and $2.5M deferred cash/shares.
- TG Therapeutics is granted an irrevocable proxy to vote the issued shares for three years.
- Includes a 'standstill' provision preventing TG Therapeutics from acquiring or restructuring Precision BioSciences for 3 years.
- Company reports approximately $116 million in cash and cash equivalents as of Dec 31, 2023 (unaudited).